Wojcieszynski Andrzej P, Hill Patrick M, Rosenberg Stephen A, Hullett Craig R, Labby Zacariah E, Paliwal Bhudatt, Geurts Mark W, Bayliss R Adam, Bayouth John E, Harari Paul M, Bassetti Michael F, Baschnagel Andrew M
1 Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Technol Cancer Res Treat. 2017 Jun;16(3):366-372. doi: 10.1177/1533034617691407. Epub 2017 Feb 7.
Magnetic resonance imaging-guided radiation therapy has entered clinical practice at several major treatment centers. Treatment of early-stage non-small cell lung cancer with stereotactic body radiation therapy is one potential application of this modality, as some form of respiratory motion management is important to address. We hypothesize that magnetic resonance imaging-guided tri-cobalt-60 radiation therapy can be used to generate clinically acceptable stereotactic body radiation therapy treatment plans. Here, we report on a dosimetric comparison between magnetic resonance imaging-guided radiation therapy plans and internal target volume-based plans utilizing volumetric-modulated arc therapy.
Ten patients with early-stage non-small cell lung cancer who underwent radiation therapy planning and treatment were studied. Following 4-dimensional computed tomography, patient images were used to generate clinically deliverable plans. For volumetric-modulated arc therapy plans, the planning tumor volume was defined as an internal target volume + 0.5 cm. For magnetic resonance imaging-guided plans, a single mid-inspiratory cycle was used to define a gross tumor volume, then expanded 0.3 cm to the planning tumor volume. Treatment plan parameters were compared.
Planning tumor volumes trended larger for volumetric-modulated arc therapy-based plans, with a mean planning tumor volume of 47.4 mL versus 24.8 mL for magnetic resonance imaging-guided plans ( P = .08). Clinically acceptable plans were achievable via both methods, with bilateral lung V20, 3.9% versus 4.8% ( P = .62). The volume of chest wall receiving greater than 30 Gy was also similar, 22.1 versus 19.8 mL ( P = .78), as were all other parameters commonly used for lung stereotactic body radiation therapy. The ratio of the 50% isodose volume to planning tumor volume was lower in volumetric-modulated arc therapy plans, 4.19 versus 10.0 ( P < .001). Heterogeneity index was comparable between plans, 1.25 versus 1.25 ( P = .98).
Magnetic resonance imaging-guided tri-cobalt-60 radiation therapy is capable of delivering lung high-quality stereotactic body radiation therapy plans that are clinically acceptable as compared to volumetric-modulated arc therapy-based plans. Real-time magnetic resonance imaging provides the unique capacity to directly observe tumor motion during treatment for purposes of motion management.
磁共振成像引导的放射治疗已在多个主要治疗中心进入临床实践。立体定向体部放射治疗早期非小细胞肺癌是这种治疗方式的一种潜在应用,因为某种形式的呼吸运动管理很重要。我们假设磁共振成像引导的三钴 - 60放射治疗可用于生成临床可接受的立体定向体部放射治疗计划。在此,我们报告磁共振成像引导的放射治疗计划与基于内部靶区体积并利用容积调强弧形治疗的计划之间的剂量学比较。
研究了10例接受放射治疗计划和治疗的早期非小细胞肺癌患者。在进行四维计算机断层扫描后,利用患者图像生成临床可实施的计划。对于容积调强弧形治疗计划,计划肿瘤体积定义为内部靶区体积 + 0.5厘米。对于磁共振成像引导的计划,使用单个吸气中期周期来定义大体肿瘤体积,然后扩展0.3厘米至计划肿瘤体积。比较治疗计划参数。
基于容积调强弧形治疗的计划的计划肿瘤体积有增大趋势,容积调强弧形治疗计划的平均计划肿瘤体积为47.4毫升,而磁共振成像引导计划为24.8毫升(P = 0.08)。两种方法均可实现临床可接受的计划,双侧肺V20分别为3.9%和4.8%(P = 0.62)。接受大于30 Gy的胸壁体积也相似,分别为22.1和19.8毫升(P = 0.78),肺立体定向体部放射治疗常用的所有其他参数也是如此。容积调强弧形治疗计划中50%等剂量体积与计划肿瘤体积的比值较低,分别为4.19和10.0(P < 0.001)。计划之间的不均匀性指数相当,分别为1.25和1.25(P = 0.98)。
与基于容积调强弧形治疗的计划相比,磁共振成像引导的三钴 - 60放射治疗能够提供临床可接受的肺部高质量立体定向体部放射治疗计划。实时磁共振成像具有在治疗期间直接观察肿瘤运动以进行运动管理的独特能力。